ABBV - Altimmune price targets lowered Tilray's next move predicted at BofA - in today's analyst action

Mario13/E+ via Getty Images Altimmune draws lower price targets on Wall Street after setback Altimmune (ALT) has extended the post-market losses in early hours today with a ~30.3% loss in the pre-market after the company announced an end to its AdCOVID COVID-19 vaccine development program. In reaction, several analysts have slashed their price target on the stock. Jefferies analyst Kelechi Chikere with a buy rating, calls the decision to discontinue the trial “a disappointment but a prudent move,” pointing to the top-line data and the company’s early-stage assets. The price target dropped by ~41.7% to ~$14.00 per share implies a ~11.9% downside. Meanwhile, highlighting that the company has a big value driver in liver disorders and obesity with ALT-801, Piper Sandler analyst Yasmeen Rahimi notes that the investors did not have much confidence in Altimmune’s vaccine program. Rahimi has an overweight rating on the stock and the price target lowered by ~80.0% to

For further details see:

Altimmune price targets lowered, Tilray’s next move predicted at BofA - in today's analyst action